会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • 9-aminoacridine derivatives and process for the preparation thereof
    • 9-氨基吖啶衍生物及其制备方法
    • US20020111491A1
    • 2002-08-15
    • US09855530
    • 2001-05-16
    • Samjin Pharmaceutical Co., Ltd.
    • Eui-Hwan ChoSun-Gan ChungSun-Hwan LeeHo-Seok KwonDong-Wook KangJeong-Ho Joo
    • C07D219/10C07D219/12
    • C07D219/10Y02P20/55
    • The present invention relates to new 9-aminoacridine derivatives of general formula (I), wherein A is hydrogen or (II) (wherein X is oxygen or sulfur, R1, R2, R3, R4 and R5 are independently hydrogen, halogen, nitro, amino, hydroxy, C1-C4 lower alkylhydroxy, C1-C4 lower alkylamino, C1-C8 alkyl, C1-C4 lower alkoxy or C1-C4 lower alkyloxycarbonyl and m and n are independently an integer of 0, 1 or 2), R6, R7, R8 and R9 are independently C1-C8 alkyl or C1-C4 lower alkoxy, and Y is hydrogen, amino, -NnullCHRnull(wherein Rnull is hydrogen, benzyl, C1-C8 alkyl or C1-C6 lower alkylamino), (III) (wherein Rnull is hydrogen, benzyl, C1-C8 alkyl or C1-C6 lower alkylamino, and Rnullnull is hydrogen, benzyl, C1-C8 alkyl or amino protecting group) or (IV) (wherein, X is as defined above, R1null, R2null, R3null, R4null and R5null are independently hydrogen, halogen, nitro, amino, hydroxy, C1-C4 lower alkylhydroxy, C1-C4 lower alkylamino, C1-C8 alkyl, C1-C4 lower alkoxy or C1-C4 lower alkylcarboxy, and q and r are independently an integer of 0, 1 or 2) or its pharmaceutically acceptable salt, and process for the preparation thereof.
    • 本发明涉及通式(I)的新的9-氨基吖啶衍生物,其中A是氢或(II)(其中X是氧或硫,R1,R2,R3,R4和R5独立地是氢,卤素,硝基, 氨基,羟基,C1-C4低级烷基羟基,C1-C4低级烷基氨基,C1-C8烷基,C1-C4低级烷氧基或C1-C4低级烷氧基羰基,m和n分别为0,1或2的整数),R6, R7,R8和R9独立地为C1-C8烷基或C1-C4低级烷氧基,Y为氢,氨基,-N = CHR'(其中R'为氢,苄基,C1-C8烷基或C1-C6低级烷基氨基) ,(III)(其中R“为氢,苄基,C 1 -C 8烷基或C 1 -C 6低级烷基氨基,R”'为氢,苄基,C 1 -C 8烷基或氨基保护基)或(Ⅳ)(其中 ,X'如上定义,R 1',R 2',R 3',R 4'和R 5'独立地是氢,卤素,硝基,氨基,羟基,C 1 -C 4低级烷基羟基,C 1 -C 4低级烷基氨基, C1-C4低级烷氧基或C1-C4低级烷基羧基,q和r独立地为a 0,1或2的整数)或其药学上可接受的盐,以及其制备方法。
    • 8. 发明申请
    • Piperazine derivatives and process for the preparation thereof
    • 哌嗪衍生物及其制备方法
    • US20030092910A1
    • 2003-05-15
    • US10105936
    • 2002-03-26
    • Samjin Pharmaceutical Co., Ltd.
    • Eui-Hwan ChoSun-Gan ChungSun-Hwan LeeHo-Seok KwonDong-Wook KangJeong-Ho JooYoung-Hee Lee
    • C07D43/02
    • C07D213/74C07D213/75C07D241/20C07D295/215
    • The present invention relates to a novel compound of the general formula (I) and its pharmaceutically acceptable acid addition salt, and process for the preparation thereof, which have strong antimumor activities and very low toxicity. 1 wherein R1 and R2 are independently hydrogen, C1-C4 alkyl, C1-C4 alkylcarboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxy, C1-C4 hydroxyalkyl, C1-C4 aminoalkyl or C1-C4 hydroxyiminoalkyl, or R1 and R2 are fused to form C3-C4 unsaturated ring; R3, R4, R5, R6 and R7 are independently hydrogen, halogen, hydroxy, nitro, amino, C1-C4 alkyl, C1-C4 alkylcarboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxy or C1-C4 thioalkoxy; R8 is C1-C4 alkyl; Y is oxygen, sulphur, amino, substituted amino or C1-C4 thioalkyl; Z is C1-C4 alkoxy, C1-C4 alkyl C1-C4 alkylamino or C1-C4 thioalkoxy; X1 and X2 are independently carbon or nitrogen; and nullNnullCnull and nullCnullYnull may form a single bond or a double bond provided that if nullNnullCnull forms a single bond, nullCnullYnull forms a double bond, and if nullCnullYnull forms a single bond, nullNnullCnull forms a double bond and R8 is nonexistent.
    • 本发明涉及一种新型的通式(I)化合物及其药学上可接受的酸加成盐及其制备方法,其具有强的抗肿瘤活性和极低的毒性。 其中R 1和R 2独立地是氢,C 1 -C 4烷基,C 1 -C 4烷基羧基,C 1 -C 4烷基羰基,C 1 -C 4烷氧基,C 1 -C 4羟基烷基,C 1 -C 4氨基烷基或C 1 -C 4羟基亚氨基烷基,或者R 1和R 2与 形成C3-C4不饱和环; R3,R4,R5,R6和R7独立地是氢,卤素,羟基,硝基,氨基,C1-C4烷基,C1-C4烷基羧基,C1-C4烷基羰基,C1-C4烷氧基或C1-C4硫代烷氧基; R8是C1-C4烷基; Y是氧,硫,氨基,取代的氨基或C 1 -C 4硫代烷基; Z是C1-C4烷氧基,C1-C4烷基C1-C4烷基氨基或C1-C4硫代烷氧基; X1和X2独立地为碳或氮; 并且-N = C-和-C = Y-可以形成单键或双键,条件是如果-N = C-形成单键,则-C = Y-形成双键,并且如果-C = Y - 形成单键,-N = C-形成双键,R8不存在。